Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Couple of studies

<< Previous

Bullboard Posts

Next >>

Comment by palinc2000on Jul 04, 2022 12:42pm

156 Views

Post# 34799448

RE:RE:RE:RE:RE:Couple of studies

What is the significance of Novo posting about meeting Thera?Why would they disclose something regarding Thera which Thera did not deem important enough to mention?

qwerty22 wrote:

I found it confusing as well but I think the flop was in an F4 cirrhosis population and they are still pushing ahead with the F2/F3 NASH population. They are also looking at combos.

PWIB123 wrote: Maybe this is secret science talk, but how do you have a Phase 2 flop where your drug made zero difference and you're still "very much on track" with that very program?